ORIGINAL RESEARCH article
Front. Med.
Sec. Translational Medicine
Interferon-Induced Transmembrane Proteins as Biomarkers for Assessing the Diagnosis and Severity of Coronary Artery Disease and Acute Myocardial Infarction
Provisionally accepted
- Meizhou People's Hospital, Meizhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Backgroud: Biomarker discovery remains pivotal for improving coronary artery disease (CAD) and acute myocardial infraction (AMI) diagnosis. While interferon-induced transmembrane proteins (IFITM1/2/3) are established in viral defense and cancer progression, their roles in cardiovascular pathologies are undefined. Methods: A retrospective cohort study was conducted, including a discovery cohort (129 CAD patients and 20 controls), a validation cohort (40 CAD patients and 16 controls) and a third cohort of 52 patients with acute myocardial infraction (AMI). Serum IFITM1/2/3 levels were specifically quantified using enzyme linked immunosorbent assay (ELISA). Coronary stenosis severity was assessed using the Gensini score. The evaluation of diagnostic performance utilized receiver operating characteristic (ROC) curves, whereas Spearman's rank test facilitated the analysis of correlations. This is a provisional file, not the final typeset article Results: Compared with controls, CAD patients exhibited significantly elevated serum IFITM1/2/3 levels (P < 0.001). ROC analysis demonstrated exceptional diagnostic accuracy for CAD detection: IFITM1 (AUC 0.9375, sensitivity 95%, specificity 81.25%), IFITM2 (AUC 0.8984, sensitivity 90%, specificity 75%), and IFITM3 (AUC 1.000, sensitivity 97.5%, specificity 100%). IFITM levels were significantly positively correlated with Gensini scores (P < 0.0001), indicating a plaque burden-dependent expression pattern. AMI patients exhibited further elevation of IFITM1/2/3 compared to patients with stable CAD (P < 0.0001), with IFITM1 specifically upregulated in AMI with heart failure (3.07 vs 4.64 ng/mL, P = 0.003). Conclusion: IFITM1/2/3 may serve as novel serum biomarkers for diagnosing CAD and AMI, as well as stratifying coronary stenosis severity, with high discriminatory capacity. Our findings position IFITMs as promising tools for precision cardiovascular risk assessment and therapeutic targeting.
Keywords: biomarkers, Coronary Artery Disease, acute myocardial infarction, IFITM1, IFITM2, IFITM3
Received: 26 Jun 2025; Accepted: 31 Oct 2025.
Copyright: © 2025 Huang, Zheng, Gan, Zhi, Zhu, Tang, Huang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mingfeng Huang, huangmingfeng@mzrmyy.com
Qionghui Huang, huangqionghui@mzrmyy.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.